Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Meade, J.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(8)
+
-
Availability
Open access
(7)
+
-
Metadata Only
(1)
+
-
Creation Date
2021
(3)
+
-
2022
(3)
+
-
Faculty
Leiden University Medical Center (LUMC)
(7)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(7)
+
-
Topic
Ripretinib
(4)
+
-
Gastrointestinal stromal tumors
(3)
+
-
Alopecia
(2)
+
-
Patient-reported outcome measures
(2)
+
-
Quality of life
(2)
+
-
Author
Meade, J.
(8)
+
-
Gelderblom, H.
(7)
+
-
George, S.
(7)
+
-
Heinrich, M.C.
(7)
+
-
Jones, R.L.
(7)
+
-
Mehren, M. von
(7)
+
-
Ruiz-Soto, R.
(7)
+
-
Attia, S.
(6)
+
-
Bauer, S.
(6)
+
-
Blay, J.Y.
(6)
+
-
Chi, P.
(6)
+
-
D'Amato, G.
(5)
+
-
Reichardt, P.
(5)
+
-
Serrano, C.
(5)
+
-
Shi, K.
(5)
+
-
Zalcberg, J.R.
(5)
+
-
Schoffski, P.
(4)
+
-
Su, Y.
(3)
+
-
Becker, C.
(2)
+
-
Razak, A.A.
(2)
+
-
Schoeffski, P.
(2)
+
-
Sherman, M.L.
(2)
+
-
Somaiah, N.
(2)
+
-
Trent, J.
(2)
+
-
Show more
Language
en
(8)
+
-
Search results
(1 - 8 of 8)
show grid
show list
save search
Constitutional microsatellite instability, genotype, and phenotype correlations in constitutional mismatch repair deficiency
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting
Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE)
Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogeneous KIT/PDGFRA mutations in the phase III INVICTUS study
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS)